Literature DB >> 27941330

Hyperosmolarity and Benzalkonium Chloride Differently Stimulate Inflammatory Markers in Conjunctiva-Derived Epithelial Cells in vitro.

Elise Warcoin1, Chloé Clouzeau, Christophe Roubeix, Anne-Laure Raveu, David Godefroy, Luisa Riancho, Christophe Baudouin, Françoise Brignole-Baudouin.   

Abstract

Tear hyperosmolarity is known to cause ocular surface inflammation in dry eye syndrome. Benzalkonium chloride (BAK), an eyedrop preservative, is known to induce dry eye in long-term-treated patients. Analyzing the modulation of the proinflammatory potential of hyperosmolarity in the presence of BAK on the conjunctiva could give new insights into the effect of this preservative on the disease. In a hyperosmolar model on a conjunctiva-derived cell line, and in the presence of BAK, we evaluated key inflammatory markers [CCL2, IL-8, IL-6, macrophage migration inhibitory factor (MIF) and intercellular adhesion molecule (ICAM)-1] as well as the osmoprotectant element nuclear factor of activated T cells (NFAT)5 using ELISA, RT-qPCR or immunofluorescence staining. Hyperosmolarity highly stimulated CCL2 and NFAT5 in these cells. BAK alone only increased IL-6 expression. The stress-combined condition stimulated CCL2, NFAT5, MIF and IL-8 secretion. ICAM-1 was not modulated by any of the conditions tested. In this model, hyperosmolarity and BAK induced the release of different proinflammatory mediators, and, when combined, they lead to the release of additional inflammatory cytokines. This in vitro study highlights the importance of avoiding long-term ophthalmic treatments containing BAK, as tear film hyperosmolarity can be a result of its detergent action.
© 2016 S. Karger AG, Basel.

Entities:  

Keywords:  Benzalkonium chloride; Inflammation; Tear hyperosmolarity

Mesh:

Substances:

Year:  2016        PMID: 27941330     DOI: 10.1159/000448117

Source DB:  PubMed          Journal:  Ophthalmic Res        ISSN: 0030-3747            Impact factor:   2.892


  6 in total

1.  Tacrolimus Loaded PEG-Cholecalciferol Based Micelles for Treatment of Ocular Inflammation.

Authors:  Shallu Kutlehria; Imran Vhora; Arvind Bagde; Nusrat Chowdhury; Gautam Behl; Ketan Patel; Mandip Singh
Journal:  Pharm Res       Date:  2018-04-16       Impact factor: 4.200

2.  Proinflammatory Markers, Chemokines, and Enkephalin in Patients Suffering from Dry Eye Disease.

Authors:  Pierre Nicolle; Hong Liang; Elodie Reboussin; Ghislaine Rabut; Elise Warcoin; Françoise Brignole-Baudouin; Stéphane Melik-Parsadaniantz; Christophe Baudouin; Antoine Labbe; Annabelle Reaux-Le Goazigo
Journal:  Int J Mol Sci       Date:  2018-04-17       Impact factor: 5.923

3.  Optical Coherence Tomography Angiography Evaluation of Conjunctival Vessels During Filtering Surgery.

Authors:  Stéphanie Hayek; Antoine Labbé; Emmanuelle Brasnu; Pascale Hamard; Christophe Baudouin
Journal:  Transl Vis Sci Technol       Date:  2019-07-03       Impact factor: 3.283

4.  Mitochondrial Dysfunctions May Be One of the Major Causative Factors Underlying Detrimental Effects of Benzalkonium Chloride.

Authors:  Anton G Rogov; Tatyana N Goleva; Evgeniya I Sukhanova; Khoren K Epremyan; Tatiana A Trendeleva; Alexandra P Ovchenkova; Dinara A Aliverdieva; Renata A Zvyagilskaya
Journal:  Oxid Med Cell Longev       Date:  2020-02-10       Impact factor: 6.543

5.  Role of CD4+ T Helper Cells in the Development of BAC-Induced Dry Eye Syndrome in Mice.

Authors:  Weijie Ouyang; Yang Wu; Xiang Lin; Shoubi Wang; Yiran Yang; Liying Tang; Zhaolin Liu; Jieli Wu; Caihong Huang; Yueping Zhou; Xiaobo Zhang; Jiaoyue Hu; Zuguo Liu
Journal:  Invest Ophthalmol Vis Sci       Date:  2021-01-04       Impact factor: 4.799

6.  Genistein-Calcitriol Mitigates Hyperosmotic Stress-Induced TonEBP, CFTR Dysfunction, VDR Degradation and Inflammation in Dry Eye Disease.

Authors:  Trailokyanath Panigrahi; Sharon D'Souza; Rohit Shetty; Archana Padmanabhan Nair; Anuprita Ghosh; Everette Jacob Remington Nelson; Arkasubhra Ghosh; Swaminathan Sethu
Journal:  Clin Transl Sci       Date:  2020-09-03       Impact factor: 4.689

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.